Improved DNA Vaccine Delivery with Needle-Free Injection Systems
| dc.contributor.author | Ledesma-Feliciano, Carmen | |
| dc.contributor.author | Chapman, Ros | |
| dc.contributor.author | Hooper, Jay W. | |
| dc.contributor.author | Elma, Kira | |
| dc.contributor.author | Zehrung, Darin | |
| dc.contributor.author | Brennan, Miles B. | |
| dc.contributor.author | Spiegel, Erin K. | |
| dc.date.accessioned | 2024-04-29T10:29:31Z | |
| dc.date.available | 2024-04-29T10:29:31Z | |
| dc.date.issued | 2023-01-28 | |
| dc.date.updated | 2023-02-24T14:09:24Z | |
| dc.description.abstract | DNA vaccines have inherent advantages compared to other vaccine types, including safety, rapid design and construction, ease and speed to manufacture, and thermostability. However, a major drawback of candidate DNA vaccines delivered by needle and syringe is the poor immunogenicity associated with inefficient cellular uptake of the DNA. This uptake is essential because the target vaccine antigen is produced within cells and then presented to the immune system. Multiple techniques have been employed to boost the immunogenicity and protective efficacy of DNA vaccines, including physical delivery methods, molecular and traditional adjuvants, and genetic sequence enhancements. Needle-free injection systems (NFIS) are an attractive alternative due to the induction of potent immunogenicity, enhanced protective efficacy, and elimination of needles. These advantages led to a milestone achievement in the field with the approval for Restricted Use in Emergency Situation of a DNA vaccine against COVID-19, delivered exclusively with NFIS. In this review, we discuss physical delivery methods for DNA vaccines with an emphasis on commercially available NFIS and their resulting safety, immunogenic effectiveness, and protective efficacy. As is discussed, prophylactic DNA vaccines delivered by NFIS tend to induce non-inferior immunogenicity to electroporation and enhanced responses compared to needle and syringe. | |
| dc.identifier | doi: 10.3390/vaccines11020280 | |
| dc.identifier.apacitation | Ledesma-Feliciano, C., Chapman, R., Hooper, Jay W., Elma, K., Zehrung, D., Brennan, Miles B., & Spiegel, Erin K. (2023). Improved DNA Vaccine Delivery with Needle-Free Injection Systems. http://hdl.handle.net/11427/39480 | en_ZA |
| dc.identifier.chicagocitation | Ledesma-Feliciano, Carmen, Ros Chapman, Jay W. Hooper, Kira Elma, Darin Zehrung, Miles B. Brennan, and Erin K. Spiegel "Improved DNA Vaccine Delivery with Needle-Free Injection Systems." (2023) http://hdl.handle.net/11427/39480 | en_ZA |
| dc.identifier.citation | Vaccines 11 (2): 280 (2023) | |
| dc.identifier.ris | TY - Journal Article AU - Ledesma-Feliciano, Carmen AU - Chapman, Ros AU - Hooper, Jay W. AU - Elma, Kira AU - Zehrung, Darin AU - Brennan, Miles B. AU - Spiegel, Erin K. AB - DNA vaccines have inherent advantages compared to other vaccine types, including safety, rapid design and construction, ease and speed to manufacture, and thermostability. However, a major drawback of candidate DNA vaccines delivered by needle and syringe is the poor immunogenicity associated with inefficient cellular uptake of the DNA. This uptake is essential because the target vaccine antigen is produced within cells and then presented to the immune system. Multiple techniques have been employed to boost the immunogenicity and protective efficacy of DNA vaccines, including physical delivery methods, molecular and traditional adjuvants, and genetic sequence enhancements. Needle-free injection systems (NFIS) are an attractive alternative due to the induction of potent immunogenicity, enhanced protective efficacy, and elimination of needles. These advantages led to a milestone achievement in the field with the approval for Restricted Use in Emergency Situation of a DNA vaccine against COVID-19, delivered exclusively with NFIS. In this review, we discuss physical delivery methods for DNA vaccines with an emphasis on commercially available NFIS and their resulting safety, immunogenic effectiveness, and protective efficacy. As is discussed, prophylactic DNA vaccines delivered by NFIS tend to induce non-inferior immunogenicity to electroporation and enhanced responses compared to needle and syringe. DA - 2023-01-28 DB - OpenUCT DP - University of Cape Town LK - https://open.uct.ac.za PY - 2023 T1 - Improved DNA Vaccine Delivery with Needle-Free Injection Systems TI - Improved DNA Vaccine Delivery with Needle-Free Injection Systems UR - http://hdl.handle.net/11427/39480 ER - | en_ZA |
| dc.identifier.uri | http://hdl.handle.net/11427/39480 | |
| dc.identifier.vancouvercitation | Ledesma-Feliciano C, Chapman R, Hooper Jay W, Elma K, Zehrung D, Brennan Miles B, et al. Improved DNA Vaccine Delivery with Needle-Free Injection Systems. 2023; http://hdl.handle.net/11427/39480. | en_ZA |
| dc.title | Improved DNA Vaccine Delivery with Needle-Free Injection Systems | |
| dc.type | Journal Article |